Nexalin Technology (NASDAQ:NXL – Get Free Report) is projected to release its results before the market opens on Friday, March 13th. Analysts expect Nexalin Technology to post earnings of ($0.12) per share and revenue of $0.08 million for the quarter.
Nexalin Technology Price Performance
NASDAQ:NXL opened at $0.43 on Thursday. The company’s fifty day moving average price is $0.56 and its 200-day moving average price is $0.88. Nexalin Technology has a 1-year low of $0.37 and a 1-year high of $2.57. The firm has a market capitalization of $7.97 million, a P/E ratio of -0.65 and a beta of 4.05.
Institutional Trading of Nexalin Technology
Several large investors have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new position in shares of Nexalin Technology during the 3rd quarter valued at about $57,000. Renaissance Technologies LLC increased its position in Nexalin Technology by 119.2% during the fourth quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock worth $68,000 after purchasing an additional 66,400 shares during the last quarter. Geode Capital Management LLC raised its stake in Nexalin Technology by 23.4% during the fourth quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock worth $84,000 after purchasing an additional 28,454 shares during the period. Finally, PEAK6 LLC acquired a new stake in shares of Nexalin Technology during the 4th quarter worth approximately $266,000. Hedge funds and other institutional investors own 0.65% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on NXL
About Nexalin Technology
Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.
The Nexalin device has received U.S.
Featured Stories
- Five stocks we like better than Nexalin Technology
- The Next Commodity Crunch (bigger than oil?)
- What a Former CIA Agent Knows About the Coming Collapse
- The gold chart Wall Street is terrified of…
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
